Linvoseltamab (REGN5458) 是一种双特异性 T 细胞衔接抗体 (BiTE)，可特异性结合 B 细胞成熟抗原 (BCMA) 和 T 细胞的 CD3，从而引导 T 细胞到达表达 BCMA 的多发性骨髓瘤 (MM) 细胞并激活 T 细胞杀死肿瘤细胞。Linvoseltamab 可用于复发/难治性多发性骨髓瘤 (RRMM) 的研究。

For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

本产品仅用作科学研究！

The detected molecular weight of Anti-BCMA & CD3 Reference Antibody (Linvoseltamab) is 145.95 kDa.

Anti-BCMA & CD3 Reference Antibody (Linvoseltamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

The purity of Anti-BCMA & CD3 Reference Antibody (Linvoseltamab) is 97.71%, determined by SEC-HPLC.

Linvoseltamab bound to BCMA protein, and then rebounded to secondary antibodies (Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Linvoseltamab bound to huBCMA-ECD-His, and the EC50 was 0.096 nM.

Linvoseltamab bound to Jurkat cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Linvoseltamab bound to Jurket cells, and the EC50 was 11.160 nM.

Linvoseltamab bound to huBCMA-HEK293 cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Linvoseltamab bound to huBCMA-HEK293 cells, and the EC50 was 2.486 nM.

Co-incubation of Linvoseltamab with Jurkat cells, then with the addition of huBCMA-HEK293 cells for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Linvoseltamab was able to activate the NF-AT signaling pathway, and the EC50 was 0.678 nM.

-80°C for 2 years under sterile conditions；-20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles.